{"id":"xylometazoline-intranasal-application","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal irritation or burning"},{"rate":null,"effect":"Sneezing"},{"rate":null,"effect":"Rebound congestion (with prolonged use)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1256400","moleculeType":"Small molecule","molecularWeight":"280.84"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to alpha-1 adrenergic receptors on nasal blood vessels, xylometazoline causes vasoconstriction that decreases mucosal edema and nasal airway obstruction. This results in improved nasal airflow and relief of congestion symptoms. The intranasal application delivers the drug directly to the site of action with minimal systemic absorption.","oneSentence":"Xylometazoline is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the nasal mucosa, reducing congestion and swelling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:21.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Nasal congestion due to rhinitis, sinusitis, or upper respiratory tract infections"},{"name":"Nasal congestion associated with allergic rhinitis"}]},"trialDetails":[{"nctId":"NCT04214938","phase":"PHASE4","title":"Hypertonic Saline Enhances The Field of View of Clinicians and Ease of Procedures","status":"COMPLETED","sponsor":"Selcuk University","startDate":"2016-02-01","conditions":"Nasopharyngeal Diseases","enrollment":200},{"nctId":"NCT02557269","phase":"PHASE4","title":"4\"S\" - Seasonal Symptoms Suppression Study","status":"UNKNOWN","sponsor":"Association Asthma, Bulgaria","startDate":"2015-05","conditions":"Seasonal Allergic Rhinitis","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Xylometazoline - intranasal application","genericName":"Xylometazoline - intranasal application","companyName":"Association Asthma, Bulgaria","companyId":"association-asthma-bulgaria","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xylometazoline is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the nasal mucosa, reducing congestion and swelling. Used for Nasal congestion due to rhinitis, sinusitis, or upper respiratory tract infections, Nasal congestion associated with allergic rhinitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}